Evidence map›Paper›PMID 30019966›Full record

ReviewExpert opinion on investigational drugs2018

N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research.

Kirsten C Morley, Andrew Baillie, Wim Van Den Brink, Kate E Chitty, Kathleen Brady, Sudie E Back, Devanshi Seth, Greg Sutherland, Lorenzo Leggio, Paul S Haber

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on investigational drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04964843 (A Pilot Study of N-acetylcysteine for Alcohol Use Disorder), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04964843 phase2withdrawnnot on this mapstarted 2023, after this paper: background citation

A Pilot Study of N-acetylcysteine for Alcohol Use Disorder

TypeinterventionalSponsorUniformed Services University of the Health SciencesRan2023 to 2025Enrolled0ConditionsAlcohol Use DisorderArmsN-acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Review
  14. Suppression of cirrhosis-related renal injury by N-acetyl cysteine.Current research in pharmacology and drug discovery · 2020
    Article
  15. Article
  16. Growing burden of alcoholic liver disease in China: A review.World journal of gastroenterology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Kirsten C Morleya University of Sydney, Faculty of Medicine and Health, Central Clinical School , NHMRC Centre of Research Excellence in Mental Health and Substance Use , Sydney , NSW , Australia.ORCID 0000-0002-0868-9928
Andrew Baillieb NHMRC Centre of Research Excellence in Mental Health and Substance Use, Faculty of Health Sciences , University of Sydney , Sydney , NSW , Australia.ORCID 0000-0003-3424-5703
Wim Van Den Brinkc Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands.
Kate E Chittyd Faculty of Medicine and Health, Discipline of Pharmacology , University of Sydney, Clinical Pharmacology and Toxicology Research Group , Sydney , NSW , Australia.
Kathleen Bradye South Carolina Clinical and Translational Research Centre , Medical University of South Carolina , Charleston , United States of America.
Sudie E Backf Department of Psychiatry and Behavioral Sciences , Medical University of South Carolina , Charleston.
Devanshi Sethg The University of Sydney, Centenary Institute , Camperdown , NSW , Australia.
Greg Sutherlandh Faculty of Medicine and Health, Discipline of Pathology , University of Sydney , Sydney , NSW , Australia.
Lorenzo Leggioi Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse , National Institutes of Health , Bethesda , MD , USA.ORCID 0000-0001-7284-8754
Paul S Habera University of Sydney, Faculty of Medicine and Health, Central Clinical School , NHMRC Centre of Research Excellence in Mental Health and Substance Use , Sydney , NSW , Australia.
The University of Sydney · AUMedical University of South Carolina · USAmsterdam UMC Location University of Amsterdam · NLNational Institute on Drug Abuse · US

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIAAA000218 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LEGGIO, LORENZO · 2013 to 2020
$22.8M
Intramural NIH HHS Z99 DA999999
6 · The paper itself

Abstract

introductionAlcoholic liver disease (ALD) is the leading cause of alcohol-related death and one of the most common forms of liver disease. Abstinence from alcohol is crucial to reducing morbidity and mortality associated with the disease. However, there are few pharmacotherapies for alcohol use disorder suitable for those with significant liver disease. AREAS COVERED: This paper presents a rationale for investigating the use of N-acetyl cysteine (NAC) to promote abstinence or reduce heavy alcohol consumption for patients with an alcohol use disorder, particularly in the presence of liver disease. NAC is an antioxidant with glutamatergic modulating and anti-inflammatory properties. Evidence is emerging that oxidative stress, neuro-inflammation and dysregulation of glutamatergic neurotransmission play a key role in alcohol use disorder. Similarly, oxidative stress is known to contribute to ALD. We outline the studies that have investigated NAC to reduce alcohol consumption including preclinical and clinical studies. We also review the evidence for NAC in other addictions as well as psychiatric and physical comorbidities associated with alcohol use disorders. EXPERT OPINION: NAC is low cost, well-tolerated and could have promise for the treatment of alcohol use disorder in the presence of liver disease. Clinical trials directly examining efficacy in this population are required.

Indexed as

AcetylcysteineAlcohol DrinkingAlcoholismAnimalsAntioxidantsHumansLiver Diseases, AlcoholicOxidative StressAcetylcysteineAntioxidantsAlcoholic liver diseasealcohol use disordercomorbidityN-acetyl cysteinepharmacotherapy

Identifiers

PMID30019966
PMCPMC12434407
OpenAlexW2884279853

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.